Who owns Avalo Therapeutics, Inc. (AVTX)? Elite investor 13F holders
2 tracked elite investors reported holding Avalo Therapeutics, Inc as of 2026-06-30, including Caligan Partners, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Caligan Partners | AVALO THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 58468244.00 USD | 3163866.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | AVALO THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 6601056.00 USD | 357200.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.